

Neratinib NALA

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



No QoL benefit

**Serious and disabling adverse effects**



Increased toxicity

**Other adjustments**



Neratinib NALA

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic setting  
 Experimental Arm: Neratinib + Capecitabine  
 Control Arm: Lapatinib plus capecitabine

